Oliver Lagore Vanvalin Investment Group Purchases 362 Shares of Eli Lilly and Company (NYSE:LLY)

Oliver Lagore Vanvalin Investment Group increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 40.9% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,247 shares of the company’s stock after buying an additional 362 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Eli Lilly and Company were worth $1,129,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after acquiring an additional 1,133,810 shares during the period. Capital World Investors lifted its position in shares of Eli Lilly and Company by 0.3% in the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock worth $15,709,466,000 after acquiring an additional 89,720 shares during the period. Capital Research Global Investors grew its holdings in shares of Eli Lilly and Company by 6.0% during the 1st quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after purchasing an additional 453,939 shares in the last quarter. Capital International Investors increased its position in shares of Eli Lilly and Company by 5.1% during the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock valued at $5,424,243,000 after purchasing an additional 335,560 shares during the period. Finally, Fisher Asset Management LLC raised its stake in shares of Eli Lilly and Company by 1.9% in the fourth quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock valued at $2,647,675,000 after purchasing an additional 85,015 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 58,749 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the completion of the transaction, the insider now owns 97,308,620 shares in the company, valued at approximately $89,062,687,541.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 423,559 shares of company stock valued at $393,136,808. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $877.50 on Friday. The stock’s fifty day simple moving average is $896.10 and its 200 day simple moving average is $842.91. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $833.98 billion, a PE ratio of 129.23, a PEG ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Guggenheim increased their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price objective for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.